[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Dyslipidemia, central obesity, hyperinsulinemia and insulin resistance, arterial hypertension, impaired glucose tolerance and increased thrombogenicity are the main features if metabolic syndrome. Metabolic syndrome is associated with increased cardiovascular risk. Fibrate administration in metabolic syndrome, apart from favourable influence on lipid profile was associated with decrease of hyperinsulinemia nad insulin resistance, reduction of systolic and diastolic blood pressure and decrease of hemostatic factors, strong predictors of increased coronary risk--fibrinogen, an acute phase reactant and factor VII was observed. Fibrate treatment was associated with slight decrease of body weight. These favourable effects of fibrates may make them particularly suitable for treatment of dyslipidemia in persons with metabolic syndrome.
Idzior-Waluś
B
B
Katedra i Klinika Chorób Metabolicznych Collegium Medicum Uniwersytet Jagielloński, 31-501 Kraków, ul. Kopernika 15.
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002994:Clofibrate / Q000627:therapeutic use; D011345:Fenofibrate / Q000627:therapeutic use; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D006946:Hyperinsulinism / Q000188:drug therapy; D006949:Hyperlipidemias / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood*; D024821:Metabolic Syndrome; D012307:Risk Factors
D000960:Hypolipidemic Agents; D008055:Lipids; D002994:Clofibrate; D011345:Fenofibrate